Navigation Links
Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension
Date:7/12/2011

SAN DIEGO, July 12, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today results from a Phase 1 clinical trial of APD811, an orally bioavailable agonist of the prostacyclin receptor which is intended for the treatment of pulmonary arterial hypertension, or PAH.

The randomized, double-blind and placebo-controlled trial evaluated the safety, tolerability and pharmacokinetics of 0.03 mg, 0.05 mg, 0.1 mg and 0.2 mg single doses of APD811. The trial evaluated 32 healthy volunteers in four cohorts of eight participants each – six randomized to APD811 and two to placebo. APD811 was rapidly absorbed and demonstrated dose-proportional pharmacokinetic exposure over the tested dose range. The terminal half-life was approximately 20 hours.

The most frequent treatment-emergent adverse events were headache, vomiting, nausea, jaw pain and flushing. Dose-limiting adverse events of nausea and vomiting occurred at the 0.2 mg dose. As compared to placebo, heart rate trended higher at the 0.05 mg, 0.1 mg and 0.2 mg doses and the corrected QT (QTc) interval trended higher at the 0.1 mg and 0.2 mg doses. Arena believes the QTc observation is not supported by preclinical data and will further evaluate this in future studies. No serious adverse events were reported.

"We are encouraged by the results of this early stage clinical trial that suggest APD811 has the potential for once-daily, oral dosing, and our next step will be to evaluate the safety, tolerability and pharmacokinetics of multiple dosing and the optimal titration schedule in a Phase 1b trial," said William R. Shanahan, M.D., Arena's Senior Vice President and Chief Medical Officer. "The development of APD811 is the result of Arena's continuing commitment to advance our diverse research and development pipeline."

About Pulmonary Arterial Hypertension (PAH)PAH is a progressi
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals Lorcaserin Achieved Statistically Significant Weight Loss
2. Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments
3. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
4. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10
5. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results and Reviews Recent Developments
6. Arena Pharmaceuticals Expands GPR119 Patent Portfolio for Type 2 Diabetes
7. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, March 11
8. Arena Pharmaceuticals Announces Upcoming Departure of Chief Financial Officer
9. Arena Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
10. Arena and Eisai Complete End-of-Review Meeting with FDA for Lorcaserin New Drug Application
11. Arena Pharmaceuticals to Host Conference Call and Webcast to Provide Update Following Lorcaserin End-of-Review Meeting With FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014  Avanir Pharmaceuticals, Inc. (NASDAQ: ... overview of the company at the Morgan Stanley Global Healthcare ... , Presentation date: Tuesday September 9, 2014 , Presentation ... webcast and 30-day archive of this presentation will be available ... Inc. Avanir Pharmaceuticals, Inc. is a biopharmaceutical company ...
(Date:9/2/2014)... N.C. , Sept. 2, 2014  Edison ... announced a partnership with the American Association for ... association of respiratory care specialists. Edison Nation Medical, ... and small business to commercialize their innovation ideas, ... association,s community of more than 50,000 respiratory therapists ...
(Date:9/2/2014)... September 2, 2014 Today, Analysts ... WLP ), Tekmira Pharmaceuticals Corporation (NASDAQ: ... ), Sanofi SA (NYSE: SNY ) and ... notes ahead of publication. To reserve complementary membership, limited ... ,WellPoint Inc. Research Reports ,WellPoint Inc. (WellPoint) posted on ...
Breaking Medicine Technology:Edison Nation Medical and AARC Team Up To Promote Innovation in Respiratory Care 2Edison Nation Medical and AARC Team Up To Promote Innovation in Respiratory Care 3Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 2Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 3Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 4Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 5Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 6
(Date:9/3/2014)... (PRWEB) September 03, 2014 Job seekers ... for their next position can now do both on ... has created a seamless tool for investigating employment and ... (massively open online courses) are closing skills gaps and ... to traditional degree programs and brick and mortar universities. ...
(Date:9/3/2014)... NJ (PRWEB) September 03, 2014 ... will be offering free screenings for depression on ... Townsquare Mall (Macy’s Court). More than 1,000 organizations ... events including hospitals, colleges and military installations. After ... to local resources and agencies that can offer ...
(Date:9/3/2014)... Joulebody, the NYC based juice and vegan ... detox and weight-loss program in time for post-summer ...     Because it’s good for celiac, diabetics, and anyone looking ...     Because using an elimination diet helps build better energy. ... letting go of caffeine, sugar, and excess meat eating ...
(Date:9/2/2014)... Autumn is well under way and famous ... season with worldwide people. Recently, it has made ... ( http://secure.hostgator.com/~affiliat/cgi-bin/affiliates/clickthru.cgi?id=seohosts ), Arvixe, and Bluehost are the ... Since 2002 HostGator has been known as a ... for reliability remains with it today. It is ...
(Date:9/2/2014)... include the sensation of grit in the eye, frequently ... are poorly understood., The researchers base their findings on ... 57) from the TwinsUK cohort, drawn from the registry ... is widely regarded as representative of the UK general ... wide range of diseases and genetic traits over the ...
Breaking Medicine News(10 mins):Health News:iHire Announces Partnership with MOOCtracks 2Health News:Screenings for Depression by Morris Psychological Group, October 9, 2014 from 4:30 to 8:30pm, Rockaway Townsquare Mall (Macy’s Court) 2Health News:Joulebody Launches a Besoke 20-Day Healthy Lifestyle Program 2Health News:Joulebody Launches a Besoke 20-Day Healthy Lifestyle Program 3Health News:Joulebody Launches a Besoke 20-Day Healthy Lifestyle Program 4Health News:Top10BestSEOHosting.com Celebrates The Coming Of Autumn And Release Reseller Hosting Suppliers Of 2014 2Health News:Around 1 in 10 UK women has dry eye disease, requiring artificial tears 2
... 23 WebMD Health Corp. (Nasdaq: WBMD ) ... that executives of WebMD are scheduled to participate at the ... 25, 2009 at 12:40 p.m. ET. Investors, analysts and ... audio broadcast of the presentation over the Internet. The ...
... On Wednesday, February 25, 2009, the Institute for ... roundtable discussion bringing leading scientists in the field of ... significance (MGUS). The event is being cochaired by James ... at the IMBCR and Robert A. Kyle, MD, who ...
... with Crain,s Cleveland Business, today presented a 2009 NorTech ... development of a Biotech Platform to Detect, Monitor, and ... developed a set of diagnostic tests used by physicians ... by determining drug resistance and disease "strength" of the ...
... #1 FOR IMMEDIATE RELEASE , Egg-irony: High cholesterol food ... Chemistry , Researchers in Canada are reporting evidence that ... may reduce another heart disease risk factor high ... that act like a popular group of prescription medications in ...
... TAMPA, Fla., Feb. 23 /PRNewswire/ -- ... data management solutions company, today announced the release ... cleanses, standardizes and integrates data from multiple platforms. ... businesses encompassing small, mid-size and "Fortune 500" companies, ...
... Sunrise Senior Living, Inc. (NYSE: SRZ ) today ... on Monday, March 2, 2009, at 9 a.m. ET to ... Mark Ordan, chief executive officer, and Richard Nadeau, chief financial ... conference call is 877-795-3638 or 719-325-4841 (from outside the U.S.). ...
Cached Medicine News:Health News:International Panel of Experts Gather for Roundtable Consensus Regarding Multiple Myeloma Related Disease 2Health News:Case Western Reserve University faculty named 2009 NorTech Innovation Award winner 2Health News:American Chemical Society's Weekly PessPac -- Feb. 18, 2009 2Health News:American Chemical Society's Weekly PessPac -- Feb. 18, 2009 3Health News:American Chemical Society's Weekly PessPac -- Feb. 18, 2009 4Health News:American Chemical Society's Weekly PessPac -- Feb. 18, 2009 5Health News:American Chemical Society's Weekly PessPac -- Feb. 18, 2009 6Health News:American Chemical Society's Weekly PessPac -- Feb. 18, 2009 7Health News:American Chemical Society's Weekly PessPac -- Feb. 18, 2009 8Health News:Industry Leading Data Quality and Householding Software Receives New Functionality for Enhanced Performance and Speed 2Health News:Sunrise to Host Conference Call and Webcast to Discuss Fourth-Quarter and Full-Year 2008 Financial Results 2
Human based assayed sera available in three levels for the control of accuracy and precision for up to 25 analytes...
CRP Liquid Conrtols level 2...
The IRN method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of iron in serum....
Enzymatic Clearance assay for the in vitro quantitative determination of LDL-cholesterol in human serum and plasma....
Medicine Products: